Immunology and inflammation

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

RayThera founders Qing Dong and Gene Hung

Biogen pens $1bn deal to buy immunology biotech RayThera

Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.

News

J&J adds rare disease wAIHA to Imaavy's potential uses

Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

Bristol Myers Squibb and Hengrui Pharma logos

BMS signs $15.2bn R&D alliance with China's Hengrui

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.

News

Autoimmune disease biotech Odyssey sets terms for $225m IPO

After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.

AbbVie climbs post-Allergan M&A peak with Apogee buy

Biogen pens $1bn deal to buy immunology biotech RayThera

J&J adds rare disease wAIHA to Imaavy's potential uses

Lilly wins new FDA approval for eczema drug Ebglyss

BMS signs $15.2bn R&D alliance with China's Hengrui

Autoimmune disease biotech Odyssey sets terms for $225m IPO

Scribe Therapeutics joins the IPO queue

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks